Assessment of microglial activation in patients with schizophrenia stratified for C4 complement by PET using [18F]DPA-714
Key facts
- Where
- Creteil és ORSAY, FranciaországSee the 2 sites
- Phase
- 2/3. fázis
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Franciaország
- Assistance Publique Hopitaux De ParisCreteil, FranciaországTaking people
- French Alternative Energies And Atomic Energy CommisionORSAY, FranciaországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institut National De La Sante Et De La Recherche Medicale
- Trial code
- EU 2023-504181-38-00
- Record updated
- 2026. március 16.
- Original description
To assess the correlation between cortical neuro-inflammation quantified by Positrons Emission Tomography (PET) using [18F]DPA-714, and genetic determinants of C4 expression in patients with schizophrenia and healthy volunteers.Read full original descriptionShow less
To assess the correlation between cortical neuro-inflammation quantified by Positrons Emission Tomography (PET) using [18F]DPA-714, and genetic determinants of C4 expression in patients with schizophrenia and healthy volunteers.
Inclusion: Male or Female, aged from 18 to 55, patients with schizophrenia diagnostic according to DSM-5 and presenting HLA 8.1 AH haplotype (8.1 AH+) or presenting no HLA 8.1 AH haplotype ( (8.1 AH-); Male or Female healthy controls aged from 18 to 55 matched regarding age, sex, HLA/C4 according to patients (8.1 AH+ or 8.1 AH-); Having Efficient Contraception for women of reproductive age ( contraception will be considered effective from the moment the patient declares the use of an oral contraceptive, the presence of an IUD other than copper ones, a diaphragm or a contraceptive implant, or the completion of a tubal ligation or sterilization by Essure process); Be able to understand research objectives and procedures; Be affiliated with or be a beneficiary of a social security scheme; Genetic criterion: TSPO genotype allowing tracer fixation (90% of subjects); Have signed a free and informed consent.
Exclusion: Participation in research or management of a pathology with ionizing radiation exposure as part of a nuclear medicine examination (PET, SPECT, NM) in the year prior to or during the exclusion period of another research; Progressive chronic inflammatory disease (rheumatic, digestive, autoimmune); For healthy volunteers only : Pathology or history of Axis 1 psychiatric pathology investigated by the validated French version of the MINI (Mini International Neuropsychiatric Interview) questionnaire; Known hypersensitivity to radiopharmaceutical ([18F]DPA-714 or one of the excipients); History of severe renal or liver failure; Contraindication to MRI : pacemaker or neurosensory pacemaker or implantable defibrillator; clip on an aneurysm or clip on a vascular malformation of the brain; ferromagnetic intraocular or cerebral foreign body; prosthesis or ferro-metallic objects or fragments mobilizable magnetic; cochlear implants; peripheral stimulator; ventriculoperitoneal neurosurgical bypass valves; permanent eye or lip makeup. Automatic injection device type insulin pump, blood glucose sensor; Adult subject to legal protection (guardianship of a tutor, or safeguard of justice); Claustrophobia; Current pregnancy, breastfeeding; Person refusing to be informed of a significant health finding discovered in the research; Person deprived of liberty by administrative or judicial decision.